Development of cognitive, motor, metabolic, and mutant huntingtin aggregation in the zQ175 mouse model of Huntington’s disease.

Development of cognitive, motor, metabolic, and mutant huntingtin aggregation in the zQ175 mouse model of Huntington’s disease.

Publication date: Oct 03, 2025

Huntington’s disease (HD) is an inherited neurodegenerative disease. In humans, the clinical diagnosis is often dependent on the emergence of motor symptoms. However, cognitive impairments and metabolic changes can be early indicators. HD mouse models are a useful tool to understand disease progression, however, relatively few studies have monitored the timeline for the emergence of cognitive indices with motor and metabolic phenotypes in parallel. In this study, cognitive, motor, and metabolic phenotypes were investigated at different ages in the zQ175 knock-in mouse alongside immunohistochemical and long-term potentiation (LTP) studies. We demonstrated that zQ175 mice developed impaired hippocampal LTP at 3-months and cognitive deficits in visuospatial attention were evident by 4-months. Long-term and spatial memory impairments emerged by 12-months, alongside motor impairments. Additionally, an anxiolytic-like phenotype emerged at 6-months. Differences in body weight were also detected from 6-months onwards, primarily driven by a reduction in fat mass. Additionally, reduced brain weight and the presence of huntingtin aggregates in the hippocampus, striatum and hypothalamus were observed at 12-months. These data support the zQ175 mouse as a model of HD, which recapitulates many aspects of the disease progression in humans and can be used to understand mechanisms underlying the disease.

Open Access PDF

Concepts Keywords
Hd Cognitive
Hippocampus Disease
Models Emergence
Neurodegenerative Hd
Zq175 Huntingtin
Huntington
Impairments
Long
Metabolic
Months
Motor
Phenotypes
Progression
Understand
Zq175

Semantics

Type Source Name
disease MESH Huntington’s disease
disease MESH neurodegenerative disease
disease MESH cognitive impairments
disease MESH disease progression
pathway REACTOME Long-term potentiation
disease MESH involuntary movements
disease MESH incoordination
disease MESH chorea
disease MESH weight loss
disease MESH anxiety
disease MESH depression
pathway REACTOME Metabolism
drug DRUGBANK Coenzyme M
disease MESH dementia
drug DRUGBANK Water
disease MESH seizures
drug DRUGBANK Albendazole

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *